To assess the transcriptional, epigenetic and functional reprogramming of circulating and tissue (BM and spleen) monocytes and myeloid progenitor cells in the context of ovarian cancer.
ID
Source
Brief title
Condition
- Miscellaneous and site unspecified neoplasms benign
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Transcriptional, epigenetic and functional signature of circulating and tissue
(BM and spleen) monocytes and myeloid progenitors of ovarian cancer patients
compared to women with bening gynaecological disease undergoing surgery for
this problem
Secondary outcome
none
Background summary
Ovarian cancer is one of the most lethal cancers in the world due to late stage
disease at diagnosis. Standard therapy consists of (interval)debulking surgery
and chemotherapy, which results in a five-year survival rate of only 30%. To
improve the patient*s outcome it is important to understand the systemic
pathophysiology of ovarian cancer, especially the role of immune cells herein.
Monocytes and myeloid progenitor cells in the circulation, bone marrow (BM) and
spleen can undergo transcriptional, epigenetic and functional reprogramming
that may contribute to ovarian cancer pathophysiology. Unravelling these
systemic processes will identify novel therapeutic targets for the treatment of
ovarian cancer.
Study objective
To assess the transcriptional, epigenetic and functional reprogramming of
circulating and tissue (BM and spleen) monocytes and myeloid progenitor cells
in the context of ovarian cancer.
Study design
Investigator-initiated, single-center explorative cross-sectional study at the
Catharina Hospital in Eindhoven.
Intervention
Assessing the in vitro effect of Beta-glucan, Lipopolysaccharide, Mifamurtide,
Heat-killed Candida an Bacillus Calmette-Guérin on trained immunity in women
with ovarian carcinoma and women with benign gynaecological disease undergoing
surgery for this problem
Study burden and risks
The risks are low. A possible complication is haematoma after venapuncture,
bonemarrow biopsy or spleen biopsy.
Michelangelolaan 2
Eindhoven 5623EJ
NL
Michelangelolaan 2
Eindhoven 5623EJ
NL
Listed location countries
Age
Inclusion criteria
Patients with ovarian carcinoma undergoinig primary debulking
Patients with ovarian carcinoma undergoinig intervaldebulking
Patiens without a malignancy undergoing surgery for benign gynaecological
conditions
Exclusion criteria
Known inflammatory or infectious diseases or an immunosuppressive status
Using medication interfering with the immune system
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL84392.000.23 |